-
Je něco špatně v tomto záznamu ?
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
P. Siriratnam, P. Sanfilippo, A. van der Walt, S. Sharmin, YC. Foong, WZ. Yeh, C. Zhu, SJ. Khoury, T. Csepany, B. Willekens, M. Etemadifar, S. Ozakbas, P. Nytrova, A. Altintas, A. Al-Asmi, B. Yamout, G. Laureys, F. Patti, M. Simo, A. Surcinelli,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
NLK
ProQuest Central
od 1944-07-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 1944-07-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1944-07-01 do Před 6 měsíci
Psychology Database (ProQuest)
od 1944-07-01 do Před 6 měsíci
PubMed
39231582
DOI
10.1136/jnnp-2024-334090
Knihovny.cz E-zdroje
- MeSH
- akvaporin 4 * imunologie MeSH
- autoprotilátky krev MeSH
- dospělí MeSH
- imunoglobulin G * krev MeSH
- imunosupresiva terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- neuromyelitis optica * imunologie farmakoterapie MeSH
- recidiva * MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. METHODS: This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. RESULTS: A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group. CONCLUSION: Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.
Alfred Health Department of Neurology Melbourne Victoria Australia
American University of Beirut Beirut Lebanon
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Istanbul Turkey
Biocruces Bizkaia Health Research Institute Barakaldo Spain
Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy
Department of Medicine CORe University of Melbourne Melbourne Victoria Australia
Department of Neurology Haydarpasa Numune Training and Research Hospital Istanbul Turkey
Department of Neurology Royal Brisbane Hospital Brisbane Queensland Australia
Department of Neurology Royal Melbourne Hospital Melbourne Victoria Australia
Department of Neurology Semmelweis University Budapest Hungary
Department of Neurology Universitair Ziekenhuis Gent Gent Belgium
Department of Neurology University of Debrecen Debrecen Hungary
Department of Neuroscience MS Center Neurology Unit S Maria delle Croci Hospital Ravenna Italy
Department of Neuroscience S Maria delle Croci Hospital Ravenna Italy
Division of Neurology Department of Medicine Amiri Hospital Kuwait City Kuwait
Faculty of Medicine Isfahan University of Medical sciences Isfahan Iran
Hunter Medical Research Institute The University of Newcastle Newcastle New South Wales Australia
Hunter New England Health John Hunter Hospital New Lambton Heights New South Wales Australia
Izmir University of Economics Medical Point Hospital İzmir Turkey
Multiple Sclerosis Research Association Izmir Turkey
Multiple Sclerosis Unit AOU Policlinico G Rodolico San Marco University of Catania Catania Italy
Neurology Department Harley Street Medical Centre Abu Dhabi UAE
Neurology Dr Etemadifar MS Institute Isfahan Iran
Neurology Galdakao Usanosolo University Hospital Osakidetza Basque Health Service Galdakao Spain
Neurology Royal Hobart Hospital Hobart Tasmania Australia
Neurology Universitair Ziekenhuis Antwerpen Edegem Belgium
Neurology Walton Centre for Neurology and Neurosurgery Liverpool UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009446
- 003
- CZ-PrNML
- 005
- 20250429135050.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/jnnp-2024-334090 $2 doi
- 035 __
- $a (PubMed)39231582
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Siriratnam, Pakeeran $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia $u Neurology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK $1 https://orcid.org/0000000347512102
- 245 10
- $a Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study / $c P. Siriratnam, P. Sanfilippo, A. van der Walt, S. Sharmin, YC. Foong, WZ. Yeh, C. Zhu, SJ. Khoury, T. Csepany, B. Willekens, M. Etemadifar, S. Ozakbas, P. Nytrova, A. Altintas, A. Al-Asmi, B. Yamout, G. Laureys, F. Patti, M. Simo, A. Surcinelli, M. Foschi, PA. McCombe, R. Alroughani, JL. Sánchez-Menoyo, R. Turkoglu, A. Soysal, J. Lechner Scott, T. Kalincik, H. Butzkueven, V. Jokubaitis, S. Huda, M. Monif, MSBASE study group
- 520 9_
- $a BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. METHODS: This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. RESULTS: A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group. CONCLUSION: Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a neuromyelitis optica $x imunologie $x farmakoterapie $7 D009471
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a akvaporin 4 $x imunologie $7 D051401
- 650 12
- $a recidiva $7 D012008
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a imunoglobulin G $x krev $7 D007074
- 650 _2
- $a autoprotilátky $x krev $7 D001323
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Sanfilippo, Paul $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
- 700 1_
- $a van der Walt, Anneke $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia $1 https://orcid.org/0000000242787003
- 700 1_
- $a Sharmin, Sifat $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia $1 https://orcid.org/0000000172949723
- 700 1_
- $a Foong, Yi Chao $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Neurology, Royal Hobart Hospital, Hobart, Tasmania, Australia
- 700 1_
- $a Yeh, Wei Zhen $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
- 700 1_
- $a Zhu, Chao $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $1 https://orcid.org/0000000339517501
- 700 1_
- $a Khoury, Samia Joseph $u Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon $u American University of Beirut, Beirut, Lebanon $1 https://orcid.org/0000000331986063
- 700 1_
- $a Csepany, Tunde $u Department of Neurology, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Willekens, Barbara $u Neurology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium $u Faculty of Medicine and Health Sciences, Translational Neurosciences Research Group, University of Antwerp, Wilrijk, Belgium
- 700 1_
- $a Etemadifar, Masoud $u Faculty of Medicine, Isfahan University of Medical sciences, Isfahan, Iran (the Islamic Republic of) $u Neurology, Dr. Etemadifar MS Institute, Isfahan, Iran (the Islamic Republic of)
- 700 1_
- $a Ozakbas, Serkan $u Izmir University of Economics, Medical Point Hospital, İzmir, Turkey $u Multiple Sclerosis Research Association, Izmir, Turkey
- 700 1_
- $a Nytrova, Petra $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Altintas, Ayse $u Department of Neurology, School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey
- 700 1_
- $a Al-Asmi, Abdullah $u College of Medicine & Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University, Al-Khodh, Oman
- 700 1_
- $a Yamout, Bassem $u Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon $u Neurology Department, Harley Street Medical Centre, Abu Dhabi, UAE
- 700 1_
- $a Laureys, Guy $u Department of Neurology, Universitair Ziekenhuis Gent, Gent, Belgium
- 700 1_
- $a Patti, Francesco $u Neuroscience, Department of Surgical and Medical Sciences and Advanced Technologies 'G.F. Ingrassia', University of Catania, Catania, Italy $u Multiple Sclerosis Unit, AOU Policlinico G Rodolico-San Marco, University of Catania, Catania, Italy
- 700 1_
- $a Simo, Magdolna $u Department of Neurology, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Surcinelli, Andrea $u Department of Neuroscience, S Maria delle Croci Hospital, Ravenna, Italy
- 700 1_
- $a Foschi, Matteo $u Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital, Ravenna, Italy $u Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy $1 https://orcid.org/0000000203217155
- 700 1_
- $a McCombe, Pamela A $u The University of Queensland, Brisbane, Queensland, Australia $u Department of Neurology, Royal Brisbane Hospital, Brisbane, Queensland, Australia $1 https://orcid.org/0000000327048517
- 700 1_
- $a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait
- 700 1_
- $a Sánchez-Menoyo, José Luis $u Neurology, Galdakao-Usanosolo University Hospital, Osakidetza-Basque Health Service, Galdakao, Spain $u Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain
- 700 1_
- $a Turkoglu, Recai $u Department of Neurology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
- 700 1_
- $a Soysal, Aysun $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey
- 700 1_
- $a Lechner Scott, Jeanette $u Hunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia $u Hunter New England Health, John Hunter Hospital, New Lambton Heights, New South Wales, Australia
- 700 1_
- $a Kalincik, Tomas $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia $u Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia $1 https://orcid.org/0000000337781376 $7 xx0121848
- 700 1_
- $a Butzkueven, Helmut $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
- 700 1_
- $a Jokubaitis, Vilija $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $1 https://orcid.org/0000000239424340
- 700 1_
- $a Huda, Saif $u Neurology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK $1 https://orcid.org/0000000309803750
- 700 1_
- $a Monif, Mastura $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia mastura.monif@monash.edu $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
- 710 2_
- $a MSBASE study group
- 773 0_
- $w MED00010064 $t Journal of neurology, neurosurgery and psychiatry $x 1468-330X $g Roč. 96, č. 4 (2025), s. 361-369
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39231582 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135045 $b ABA008
- 999 __
- $a ok $b bmc $g 2311060 $s 1246527
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 96 $c 4 $d 361-369 $e 20250324 $i 1468-330X $m Journal of neurology, neurosurgery and psychiatry $n J Neurol Neurosurg Psychiatry $x MED00010064
- LZP __
- $a Pubmed-20250415
